Cargando…

A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience

BACKGROUND: Medulloblastoma (MB) has been classified into four core subgroups according to the transcriptional profile in recent years. However, some disagreement among researchers remains regarding the prognoses and most effective treatments of the different subgroups with different age distributio...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Tao, Zhang, Yuqi, Wang, Junmei, Du, Jiang, Raynald, Qiu, Xiaoguang, Wang, Ying, Li, Chunde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427081/
https://www.ncbi.nlm.nih.gov/pubmed/28553259
http://dx.doi.org/10.3389/fneur.2017.00198
_version_ 1783235595325145088
author Jiang, Tao
Zhang, Yuqi
Wang, Junmei
Du, Jiang
Raynald,
Qiu, Xiaoguang
Wang, Ying
Li, Chunde
author_facet Jiang, Tao
Zhang, Yuqi
Wang, Junmei
Du, Jiang
Raynald,
Qiu, Xiaoguang
Wang, Ying
Li, Chunde
author_sort Jiang, Tao
collection PubMed
description BACKGROUND: Medulloblastoma (MB) has been classified into four core subgroups according to the transcriptional profile in recent years. However, some disagreement among researchers remains regarding the prognoses and most effective treatments of the different subgroups with different age distributions. OBJECTIVE: The objective of this study was to analyze MB prognosis in children population based on the classification of four molecular subgroups. METHODS: From January 2011 to January 2013, 84 consecutive MB patients aged underwent tumor removal at Beijing Tiantan Hospital. A total of 55 patients who ranged in age from 4 to 18 years underwent detailed follow-up. Molecular subgrouping was performed using RT-PCR. RESULTS: The 2-year progression-free survival (PFS) and overall survival (OS) rates for the entire cohort were 76.2 ± 5.8 and 81.8 ± 5.2%, respectively. Univariate analysis revealed that the Group 4 patients had a better survival (2-year OS, 90.6 ± 5.2%) than the SHH subgroup (P = 0.002) and Group 3 patients (P = 0.008). Only two of the 23 non-metastasized Group 4 patients relapsed, and chemotherapy did significantly affect these patients (PFS, P = 0.685). One out of five WNT patients had tumor relapse and died at last. Large cell/anaplastic (LC/A) histology and chemotherapy were independent risk factors in multivariate analysis. CONCLUSION: In our study, the non-metastasized Group 4 patients had an excellent prognosis. The SHH subgroup and Group 3 patients had worst prognoses. LC/A histology had a dismal prognosis in our cohorts, which warrants intensive treatment.
format Online
Article
Text
id pubmed-5427081
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54270812017-05-26 A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience Jiang, Tao Zhang, Yuqi Wang, Junmei Du, Jiang Raynald, Qiu, Xiaoguang Wang, Ying Li, Chunde Front Neurol Neuroscience BACKGROUND: Medulloblastoma (MB) has been classified into four core subgroups according to the transcriptional profile in recent years. However, some disagreement among researchers remains regarding the prognoses and most effective treatments of the different subgroups with different age distributions. OBJECTIVE: The objective of this study was to analyze MB prognosis in children population based on the classification of four molecular subgroups. METHODS: From January 2011 to January 2013, 84 consecutive MB patients aged underwent tumor removal at Beijing Tiantan Hospital. A total of 55 patients who ranged in age from 4 to 18 years underwent detailed follow-up. Molecular subgrouping was performed using RT-PCR. RESULTS: The 2-year progression-free survival (PFS) and overall survival (OS) rates for the entire cohort were 76.2 ± 5.8 and 81.8 ± 5.2%, respectively. Univariate analysis revealed that the Group 4 patients had a better survival (2-year OS, 90.6 ± 5.2%) than the SHH subgroup (P = 0.002) and Group 3 patients (P = 0.008). Only two of the 23 non-metastasized Group 4 patients relapsed, and chemotherapy did significantly affect these patients (PFS, P = 0.685). One out of five WNT patients had tumor relapse and died at last. Large cell/anaplastic (LC/A) histology and chemotherapy were independent risk factors in multivariate analysis. CONCLUSION: In our study, the non-metastasized Group 4 patients had an excellent prognosis. The SHH subgroup and Group 3 patients had worst prognoses. LC/A histology had a dismal prognosis in our cohorts, which warrants intensive treatment. Frontiers Media S.A. 2017-05-12 /pmc/articles/PMC5427081/ /pubmed/28553259 http://dx.doi.org/10.3389/fneur.2017.00198 Text en Copyright © 2017 Jiang, Zhang, Wang, Du, Raynald, Qiu, Wang and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Jiang, Tao
Zhang, Yuqi
Wang, Junmei
Du, Jiang
Raynald,
Qiu, Xiaoguang
Wang, Ying
Li, Chunde
A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience
title A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience
title_full A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience
title_fullStr A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience
title_full_unstemmed A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience
title_short A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience
title_sort retrospective study of progression-free and overall survival in pediatric medulloblastoma based on molecular subgroup classification: a single-institution experience
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427081/
https://www.ncbi.nlm.nih.gov/pubmed/28553259
http://dx.doi.org/10.3389/fneur.2017.00198
work_keys_str_mv AT jiangtao aretrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT zhangyuqi aretrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT wangjunmei aretrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT dujiang aretrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT raynald aretrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT qiuxiaoguang aretrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT wangying aretrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT lichunde aretrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT jiangtao retrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT zhangyuqi retrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT wangjunmei retrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT dujiang retrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT raynald retrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT qiuxiaoguang retrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT wangying retrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience
AT lichunde retrospectivestudyofprogressionfreeandoverallsurvivalinpediatricmedulloblastomabasedonmolecularsubgroupclassificationasingleinstitutionexperience